key: cord-0048060-b7wp882o
authors: Kaushik, Shubhi; Derespina, Kim R.; Medar, Shivanand S.
title: Reply
date: 2020-07-24
journal: J Pediatr
DOI: 10.1016/j.jpeds.2020.07.064
sha: b4c6d41253fd95e14cd98bc0eb4b3eb79c93a7a4
doc_id: 48060
cord_uid: b7wp882o

nan

Centers for Disease Control (CDC), vastly differing treatment modalities ranging from supportive care to immunomodulating agents and plasma infusion have been implemented with a lack of consensus on how to best treat this condition. Reassuringly, MIS-C thus far has been associated with low mortality.

Our study was designed to include critically ill children and adolescents who met criteria for SARS-CoV-2 associated MIS-C. Some patients in our series also may have met Kawasaki disease criteria. Whether "overlap" patients have Kawasaki disease, atypical Kawasaki disease, Kawasaki disease with macrophage activation syndrome or represent a spectrum of MIS-C requires ongoing surveillance and longer term follow up.

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Multisystem Inflammatory Syndrome in Children

Multisystem Inflammatory Syndrome in Children (MIS-C) and Kawasaki Disease: Two Different Illnesses with Overlapping Clinical Features